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Abstract: BACKGROUND: It is currently unknown whether acute exposure to n3 fatty acid–containing
fish oil–based lipid emulsion Omegaven as opposed to the n6 fatty acid–containing soybean oil–based lipid
emulsion Intralipid is more favorable in terms of insulin signaling and glucose uptake in the intact beating
heart. METHODS: Sprague–Dawley rat hearts were perfused in the working mode for 90 minutes in the
presence of 11 mM glucose and 1.2 mM palmitate bound to albumin, the first 30 minutes without insulin
followed by 60 minutes with insulin (50 mU/L). Hearts were randomly allocated to 100 µM Intralipid,
100 µM Omegaven, or no emulsion (insulin treatment alone) for 60 minutes. Glycolysis and glycogen
synthesis were measured with the radioactive tracer [5-3H]glucose, and glucose uptake was calculated.
Phosphorylation of protein phosphatase 2A (PP2A), protein kinase Akt, and phosphofructokinase (PFK)-
2 was measured by immunoblotting. Glycolytic metabolites were determined by enzymatic assays. Mass
spectrometry was used to establish acylcarnitine profiles. Nuclear factor ฀B (NF฀B) nuclear translocation
served as reactive oxygen species (ROS) biosensor. RESULTS: Insulin-mediated glucose uptake was
decreased by Intralipid (4.9 ± 0.4 vs 3.7 ± 0.3 ฀mol/gram dry heart weight [gdw]·min; P = .047)
due to both reduced glycolysis and glycogen synthesis. In contrast, Omegaven treatment did not affect
insulin-mediated glycolysis or glycogen synthesis and thus preserved glucose uptake (5.1 ± 0.3 vs 4.9 ±
0.4 ฀mol/gdw·min; P = .94). While Intralipid did not affect PP2A phosphorylation status, Omegaven
resulted in significantly enhanced tyrosine phosphorylation and inhibition of PP2A. This was accompanied
by increased selective threonine phosphorylation of Akt and the downstream target PFK-2 at S483.
PFK-1 activity was increased when compared with Intralipid as measured by the ratio of fructose 1,6-
bisphosphate to fructose 6-phosphate (Omegaven 0.60 ± 0.11 versus Intralipid 0.47 ± 0.09; P = .023),
consistent with increased formation of fructose 2,6-bisphosphate by PFK2, its main allosteric activator.
Omegaven lead to accumulation of acylcarnitines and fostered a prooxidant response as evidenced by NF฀B
nuclear translocation and activation. CONCLUSIONS: Omegaven as opposed to Intralipid preserves
glucose uptake via the PP2A–Akt–PFK pathway in intact beating hearts. n3 fatty acids decelerate ฀-
oxidation causing accumulation of acylcarnitine species and a prooxidant response, which likely inhibits
redox-sensitive PP2A and thus preserves insulin signaling and glucose uptake.
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KEY POINTS
• Question: How do lipid emulsions containing n3 fatty acids affect insulin signaling and glu-
cose uptake in the intact beating heart?
• Finding: Using perfused rat hearts, we show that a lipid emulsion containing high amounts of 
n3 fatty acids (Omegaven) as opposed to n6 fatty acids (Intralipid) preserves insulin signaling, 
glycolysis, and glucose uptake possibly by inhibition of protein phosphatase 2A.
• Meaning: Omegaven compared to Intralipid does not induce insulin resistance and thus has 
more favorable metabolic effects in the beating heart.
BACKGROUND: It is currently unknown whether acute exposure to n3 fatty acid–containing 
fish oil–based lipid emulsion Omegaven as opposed to the n6 fatty acid–containing soybean 
oil–based lipid emulsion Intralipid is more favorable in terms of insulin signaling and glucose 
uptake in the intact beating heart.
METHODS: Sprague–Dawley rat hearts were perfused in the working mode for 90 minutes in the 
presence of 11 mM glucose and 1.2 mM palmitate bound to albumin, the first 30 minutes with-
out insulin followed by 60 minutes with insulin (50 mU/L). Hearts were randomly allocated to 
100 µM Intralipid, 100 µM Omegaven, or no emulsion (insulin treatment alone) for 60 minutes. 
Glycolysis and glycogen synthesis were measured with the radioactive tracer [5-3H]glucose, 
and glucose uptake was calculated. Phosphorylation of protein phosphatase 2A (PP2A), pro-
tein kinase Akt, and phosphofructokinase (PFK)-2 was measured by immunoblotting. Glycolytic 
metabolites were determined by enzymatic assays. Mass spectrometry was used to establish 
acylcarnitine profiles. Nuclear factor κB (NFκB) nuclear translocation served as reactive oxygen 
species (ROS) biosensor.
RESULTS: Insulin-mediated glucose uptake was decreased by Intralipid (4.9 ± 0.4 vs 3.7 ± 
0.3 μmol/gram dry heart weight [gdw]·min; P = .047) due to both reduced glycolysis and gly-
cogen synthesis. In contrast, Omegaven treatment did not affect insulin-mediated glycolysis or 
glycogen synthesis and thus preserved glucose uptake (5.1 ± 0.3 vs 4.9 ± 0.4 μmol/gdw·min; 
P = .94). While Intralipid did not affect PP2A phosphorylation status, Omegaven resulted in sig-
nificantly enhanced tyrosine phosphorylation and inhibition of PP2A. This was accompanied by 
increased selective threonine phosphorylation of Akt and the downstream target PFK-2 at S483. 
PFK-1 activity was increased when compared with Intralipid as measured by the ratio of fructose 
1,6-bisphosphate to fructose 6-phosphate (Omegaven 0.60 ± 0.11 versus Intralipid 0.47 ± 
0.09; P =  .023), consistent with increased formation of fructose 2,6-bisphosphate by PFK2, 
its main allosteric activator. Omegaven lead to accumulation of acylcarnitines and fostered a 
prooxidant response as evidenced by NFκB nuclear translocation and activation.
CONCLUSIONS: Omegaven as opposed to Intralipid preserves glucose uptake via the PP2A–Akt–
PFK pathway in intact beating hearts. n3 fatty acids decelerate β-oxidation causing accumulation 
of acylcarnitine species and a prooxidant response, which likely inhibits redox-sensitive PP2A 
and thus preserves insulin signaling and glucose uptake.  (Anesth Analg 2020;130:37–48)
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Omegaven Preserves Glucose Uptake in the Heart
M
illions of patients worldwide depend on 
total or partial parenteral nutrition contain-
ing lipid emulsions. Indications for paren-
teral nutrition with lipid emulsions include critically 
ill patients admitted to the intensive care unit, short- 
or long-term intestinal failure, severe malnutrition, 
cancer, pancreatitis, major trauma, burns, and certain 
surgeries.1 In these large groups of patients requir-
ing parenteral nutrition, mixtures containing lipid 
emulsions as opposed to exclusive high-carbohydrate 
solutions are preferred because a more physiological 
provision of calories can be achieved. However, lipid 
emulsions elicit insulin resistance and adverse meta-
bolic effects on glucose metabolism,2 particularly in 
already metabolically compromised patients.3 These 
metabolic changes also affect cardiac function4 and 
ultimately impair patient outcomes.5
Insulin resistance is a key feature of type 2 diabetic 
metabolism and is defined as impaired sensitivity to 
effects of insulin on whole-body glucose disposal. In the 
heart, it is defined as the reduced ability of the heart to 
increase glucose uptake in response to insulin stimu-
lation.6 Cardiac insulin resistance ultimately reduces 
cardiac performance.7 Intralipid (Fresenius Kabi AG, 
Bad Homburg, Germany), a soybean oil–based prod-
uct containing long-chain n6 fatty acids, is the most 
prevalently used lipid emulsion in medicine to date.8 
However, infusion of Intralipid, for example, as part 
of parenteral nutrition, impairs glucose uptake via the 
Randle cycle9 and reduces insulin sensitivity in both 
healthy volunteers and diabetic subjects.10,11 In contrast, 
lipid emulsions containing n3 polyunsaturated fatty 
acids such as eicosapentaenoic acid (EPA, C20:5 n3) and 
docosahexaenoic acid (DHA, C22:6 n3) may have ben-
eficial effects on glucose metabolism and prevent lipid-
induced insulin resistance.12 While cell-based studies 
suggest beneficial effects of lipid emulsions with DHA 
and EPA such as Omegaven (Fresenius Kabi AG, Bad 
Homburg, Germany) on cardiac glucose metabolism,13 it 
has never been tested in the intact beating heart whether 
Omegaven as opposed to Intralipid more favorably 
affects insulin-mediated glucose uptake, and a direct 
comparison of the cardiometabolic effects of these lipid 
emulsions is warranted. We hypothesized that acute 
administration of Omegaven as opposed to Intralipid 
would preserve glucose uptake in the heart in the pres-
ence of the fatty acid palmitate, a condition mimicking 
stress and promoting insulin insensitivity. Because pre-
vious reports in cells implicated inhibition of the serine/
threonine protein phosphatase 2A (PP2A) in beneficial 
effects of polyunsaturated fatty acids on insulin sig-
naling,14 we further tested whether Omegaven would 
inhibit PP2A and enhance Akt signaling by phosphory-
lating and activating its downstream target phospho-
fructokinase (PFK)-2, and thus ultimately increase the 
activity of the rate-limiting enzyme of glycolysis, PFK-1.
METHODS
The investigation conforms to the Guide for the Care 
and Use of Laboratory Animals published by the 
US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996) and adheres to the Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) 
guidelines (https://www.nc3rs.org.uk/arrive-guide-
lines). The experimental protocol used in this inves-
tigation was approved by the University of Alberta 
Animal Policy and Welfare Committee.
All materials were from Sigma-Aldrich (Oakville, 
ON, Canada) unless otherwise stated.
Working Heart Perfusions and Protocols
Sprague–Dawley rats (14 weeks of age) were anesthe-
tized with pentobarbital (150 mg/kg, intraperitone-
ally). Each heart was rapidly removed and perfused 
initially in a nonworking Langendorff mode with 
Krebs–Henseleit solution for 15 minutes. The work-
ing mode perfusion was subsequently established 
(11.5 mm Hg preload, 80 mm Hg afterload, 5 Hz) 
with a recirculating perfusate of 100 mL (37°C; pH, 
7.4) gassed with 95% oxygen (O2)/5% carbon dioxide 
(CO2) mixture that consisted of a modified Krebs–
Henseleit solution containing (mmol/L) KCl (4.7), 
NaCl (118), KH2PO4 (1.2), MgSO4 (1.2), CaCl2 (2.5), 
NaHCO3 (25), glucose (11), palmitate (1.2, prebound 
to 3% bovine serum albumin), and no insulin for 
the first 30 minutes followed by a 60-minute perfu-
sion with insulin 50 mU/L. Some hearts were per-
fused without insulin for 90 minutes. Cardiac output 
(CO; mL/min) and aortic flow (mL/min) were mea-
sured using ultrasonic flow probes (Transonic T206; 
Transonic Systems Inc, Ithaca, NY) placed in the left 
atrial inflow and the aortic outflow lines. Left ven-
tricular work (LVW; mL/min·mm Hg) was calculated 
as LVW CO  aortic systolic pressure preload= × −( ). 
Coronary flow (mL/min) was calculated as the dif-
ference between CO and aortic flow, and coronary 
vascular conductance (mL/min mm Hg) was com-
puted as CVC =  coronary flow × (mean aortic pressure 
– preload). Measurements of mechanical function were 
averaged for the initial 30 minutes of aerobic perfu-
sion without insulin (baseline) in the perfusate and 
for the following 60 minutes of perfusion in the pres-
ence of 50 mU/L insulin (response to insulin). Hearts 
were randomly assigned to the following 4 groups 
(N  =  7 per group; see Figure  1): (1) hearts perfused 
for 90 minutes without insulin (no-INS); (2) hearts 
perfused without insulin for 30 minutes followed by 
60 minutes with insulin (INS); and (3 and 4) hearts 
treated with 100 µM Intralipid (INS/IL) or 100 µM 
Omegaven (INS/OV; Fresenius Kabi Switzerland AG, 
Oberdorf, Switzerland). Previous studies with total 
parenteral nutrition in rats showed plasma triglycer-
ide concentrations in the range of 100–500 µM.15 An 
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average molecular weight of 873 g/M was calculated 
for Intralipid and 913 g/M for Omegaven, respec-
tively, based on the composition of the 2 emulsions 
as detailed in Supplemental Digital Content, Table 1, 
http://links.lww.com/AA/C857. The n6-to-n3 ratio 
for Intralipid is 7:1 and for Omegaven is 1:8. Intralipid 
contains α-linolenic acid (C18:3 n3), which shows 
limited conversion to EPA and DHA in mammals.16 
Additional hearts were perfused for 30 minutes to 
determine the glycogen content necessary for the cal-
culation of the glucose uptake (see formula below). 
At the end of the perfusions, the left ventricles were 
collected and all hearts were immediately frozen in 
liquid nitrogen with Wollenberger clamps and stored 
at −80°C for subsequent molecular analyses.
Metabolic Flux Measurements of Glycolysis
Glycolysis rates were determined by perfusing hearts 
with [5-3H]glucose. Total myocardial 3H2O production 
liberated from [5-3H]glucose at the enolase step of gly-
colysis was determined every 10 minutes. The rates 
expressed as μmol/gdw · min were calculated for each 
time interval. Averaged values were calculated for the 
30-minute perfusion without insulin and for the subse-
quent 60 minutes with insulin.
Glycogen Content and [5-3H]Glucose 
Incorporation
Glycogen content (in µmol glucosyl units/gdw) was 
determined by powdering heart tissue samples and 
subjecting to alkaline extraction with 30% potassium 
hydroxide (KOH) followed by ethanol precipita-
tion and acid hydrolysis (2 N H2SO4) and analysis of 
glucose content. Incorporation of [5-3H]glucose into 
glycogen was counted.6
Glucose Uptake in Perfused Working Hearts
Glucose uptake (in µmol glucose/gdw · min) was cal-
culated taking into account the 2 fates of glucose sub-
jected to intermediary metabolism, that is, metabolism 
by glycolysis and incorporation into glycogen.6 The 
average rate of glucose uptake in the time interval 
30–90 minutes (GU[30–90]) (treatment period) is the sum 
of the rate of glycolysis and the rate of glycogen syn-
thesis (abbreviated as GG[30–90]):
GU mmol g minute =




− − × ×
lysis mmol g minute +
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Glycogen synthesis in the time interval 30–90 min-
utes (treatment period; GG[30–90]) is calculated from 
the total amount of newly synthesized glycogen mea-
sured at the end of the protocol (90 minutes) and the 
average rate of glycogen synthesis in the first 30 min-
utes (GG[0–30]) determined from separate experiments:
"Hot" glycogen content mmol g =




















Glycolytic Metabolites, Citrate Concentrations, 
Pyruvate Dehydrogenase Activity, and Nuclear 
Factor κB Activation
Glucose 6-phosphate, fructose 6-phosphate (F6P), and 
fructose 1,6-bisphosphate (F1,6BP) levels (nmol/g wet 
Figure 1.  Experimental protocols. After a 15-min period of Langendorff (nonworking) stabilization period, the working mode was established. 
Hearts were randomly assigned to the following groups. no-INS: hearts perfused for 90 min without insulin (time-matched control); INS: hearts 
perfused for 30 min without insulin followed by 60 min with insulin (50 mU/L); INS/IL: hearts were perfused identical to INS hearts, but 
Intralipid was added 5 min before insulin administration; and INS/OV: hearts were perfused identical to INS hearts, but Omegaven was added 
5 min before insulin administration. Arrows indicate timing of lipid emulsion administration. INS indicates insulin alone; INS/IL, perfusion with 
insulin plus Intralipid; INS/OV, perfusion with insulin plus Omegaven; K-H, Krebs–Henseleit solution buffer containing 11 mM glucose and 1.2 
mM palmitate bound to albumin; no-INS, perfusion without insulin.
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weight) were determined by a coupled enzymatic assay 
after deproteinizing samples with perchloric acid.17 
Citrate was determined from heart tissue homogenate 
using a commercially available kit (Abcam [Cambridge, 
MA] #ab83396) according to manufacturer’s instruc-
tions. Nuclear factor κB (NFκB) (p65) deoxyribonucleic 
acid (DNA)-binding activity was assayed using nuclear 
fractions prepared as recommended by the manu-
facturer (Thermo Scientific, Oakville, ON). Pyruvate 
dehydrogenase (PDH) activity (mOD/min/mg) was 
measured using commercially available kits (Abcam 
#ab109902).
Immunoblotting
Total tissue lysate was prepared from frozen cardiac 
samples in ice-cold lysis buffer containing 50 mM Tris 
(pH, 8.0), 150 mM NaCl, 1% nonyl phenoxypolye-
thoxylethanol (NP-40), 0.1% sodium dodecyl sulfate 
(SDS), and 0.5% sodium deoxycholate (supplemented 
with protease and phosphatase inhibitor cocktail mix), 
and the supernatant after centrifugation at 1000g 
(10 minutes, 4°C) was collected. Plasma membrane–
enriched fractions were prepared.18 Protein concentra-
tions were quantified by Bradford assay and boiled in 
5× SDS-loading buffer (except for plasma membrane 
fractions). Equal amount of protein samples (20–25 
µg) was loaded, separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), and 
transferred to nitrocellulose membrane for detection 
with antibodies of interest. Immunoreactivity was visu-
alized using an enhanced chemiluminescence (ECL) 
reagent (GE HealthCare, Mississauga, ON, Canada), 
and its intensity was quantified using ImageJ software 
(http://rsbweb.nih.gov/ij/). The following antibod-
ies were from (1) Cell Signaling Technology (Danvers, 
MA): p-Akt (Ser473 and Thr308; #9271 and #9272), 
total Akt (#9272), p-AMPKα (Thr172; #2531), total 
AMPKα (#2532), p-GSK3β (Ser9; #9336), total glyco-
gen synthase kinase 3β (GSK3β) (#9315); (2) Abcam Inc 
(Cambridge, MA): CD36 (#ab133625), phosphoinosit-
ide-dependent protein kinase (PDK)-4 (#ab214938), 
p-p70S6K1 (Thr389; #ab2571), total p70S6K1 (#ab9366), 
α-tubulin (#ab7291), vinculin (#ab18058); (3) Santa 
Cruz Biotechnology (Dallas, TX): p-PFK2 car (Ser466 
and Ser483; #sc32966 and #sc373806), p-PP2A-C α/β 
(Tyr307, #sc271903), PP2A-C (#sc80665), demethyl-
ated-PP2A-C (#sc13601), PP2A-B55α (#sc81606); (4) 
Novus Biologicals (Littleton, CO): GLUT4 (#NBP1-
49840), Na+/K+-ATPase α1 (#NB300-146SS); (5) Aviva 
Systems Biology (San Diego, CA): PFK2 (#ARP56677); 
and (6) Sigma-Aldrich (St Louis, MO): α-tubulin 
(#T6074). Loading controls (α-tubulin, vinculin, Na+/
K+-ATPase α1) were used where appropriate. Because 
no satisfying blotting conditions could be established 
for both antibodies phospho- and total PFK2 on the 
same membrane, phospho-to-total PFK2 ratios were 
determined from separate blots for p-PFK2 and total 
PFK2, each normalized to the respective loading con-
trols, to obtain high-quality signals.
Acylcarnitine Profiling of Cardiac Tissue Using 
Mass Spectrometry
Tissue levels of 32 acylcarnitine species were mea-
sured using electrospray ionization tandem mass 
spectrometry. Acylcarnitines were extracted from 
heart tissue with methanol and quantified using 8 
isotopically labeled internal standards (Cambridge 
Isotopes Laboratories, Andover, MA). Precursor ions 
of m/z 85 in the mass range of m/z 150–450 were 
acquired on a PE SCIEX API 365 LC-ESI-MS/MS 
instrument (Applied Biosystems, Foster City, CA).6,19
Statistical Analysis
Values are given as mean (standard deviation [SD]) 
or median (25th–75th percentile) depending on the 
underlying data distribution (normal versus skewed) 
for the indicated number of independent observa-
tions (N). The significance of differences in metabolic 
variables (such as glucose uptake, glycogen levels, 
and protein phosphorylation levels) among groups 
was determined by ANOVA followed by the Tukey 
method for post hoc analysis or by nonparametric 
methods (Kruskal–Wallis test followed by Dunn test 
for post hoc analysis) depending on the underly-
ing data distribution. Two-way repeated-measures 
analysis of variance (ANOVA) was used to analyze 
glycolysis data as well as hemodynamic data. This 
was followed by all pairwise multiple comparison 
procedures (Holm–Sidak method) if appropriate to 
determine which group differences were statistically 
significant. Differences are considered statistically 
significant if the overall P < .05 (2-sided). SigmaPlot 
(version 13.0; Systat Software, Inc, Chicago, IL) was 
used for the analyses. A sample size estimate was 
calculated based on our previous results.6 With an 
expected difference in the main independent vari-
able (glucose uptake) of 1 μmol·gram dry heart 
weight [gdw]−1·minute−1, a SD of 0.5 μmol·gdw−1·min
ute−1, an α level of .05 (2-sided), a power of 0.8, and 4 
groups (no-INS, INS, INS/IL, and INS/OV; Figure 1) 
in a 1-way ANOVA design, a minimum sample size 
of N = 7 hearts per group was calculated.
RESULTS
Cardiac Performance Remains Stable in the 
Presence of the Lipid Emulsions Omegaven and 
Intralipid
A summary of the hemodynamic measurements 
is given in Supplemental Digital Content, Table 
2, http://links.lww.com/AA/C857. LVW and 
CO were unchanged after insulin administration. 
Administration of Intralipid or Omegaven did not 
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affect any of the measured parameters including heart 
rate, coronary flow, CO, and LVW.
Omegaven as Opposed to Intralipid Preserves 
Glycolysis, Glycogen Synthesis, and Glucose 
Uptake
Administration of insulin to the perfusate, contain-
ing 11 mM glucose and 1.2 mM palmitate bound to 
albumin, for 60 minutes after 30 minutes of perfu-
sion without insulin increased glycolysis (INS base-
line 2.58 ± 0.28 μmol/gdw·min versus INS response 
3.91 ± 0.30 μmol/gdw·min; P < .001), while glycoly-
sis did not change without insulin administration 
(no-INS baseline 1.77 ± 0.15 μmol/gdw·min versus 
no-INS response 1.51 ± 0.15 μmol/gdw·min; P = .27). 
Administration of insulin also increased incorpora-
tion of radioactive glucose into glycogen (INS 73.4 
μmol/gdw [42.0–112.4 μmol/gdw] versus no-INS 41.4 
μmol/gdw [38.5–44.6 μmol/gdw]; P = .042) and glu-
cose uptake (INS 4.9 ± 0.4 μmol/gdw·min versus no-
INS 1.9 ± 0.2 μmol/gdw·min; P < .001) (Figure 2A–C). 
Intralipid administration markedly diminished the 
insulin response, as evidenced by reduced glycolysis 
(INS/IL response 3.03 ± 0.3 μmol/gdw·min versus 
INS response 3.91 ± 0.30 μmol/gdw·min; P  =  .038) 
and reduced net glucose uptake (INS/IL 3.7 ± 0.3 
μmol/gdw·min versus INS 4.9 ± 0.4 μmol/gdw·min; 
P = .047). In contrast, Omegaven did not reduce gly-
colysis (INS/OV response 4.11 ± 0.24 μmol/gdw·min 
versus INS response 3.91 ± 0.30 μmol/gdw·min; 
P = .59) and fully preserved glucose uptake (INS/OV 
5.1 ± 0.3 μmol/gdw·min versus INS 4.9 ± 0.4 μmol/
gdw·min; P = .94) (Figure 2A–C). Consistent with fatty 
acid–induced inhibition of glucose oxidation (Randle 
cycle), Intralipid reduced PDH activity (INS/IL 18.7 
mOD/min/mg [15.3–21.0 mOD/min/mg] versus 
INS 31.7 mOD/min/mg [22.0–40.8 mOD/min/mg]; 
P = .019) (Figure 3A), while PDK4 protein levels were 
unchanged (Figure  3B). Conversely, administration 
of Omegaven did not reduce PDH activity (INS/
OV 24.6 mOD/min/mg [23.8–36.5 mOD/min/mg] 
versus INS 31.7 mOD/min/mg [22.0–40.8 mOD/
min/mg]; P = 1.000). Translocation of GLUT4 to the 
sarcolemma in response to insulin was unaffected in 
Intralipid- or Omegaven-treated hearts (Figure  3C). 
There was a trend to higher GSK3β phosphorylation 
in Omegaven-treated hearts, but this did not reach sta-
tistical significance (Figure 3D). Analysis of glycolytic 
intermediates (Supplemental Digital Content, Table 3, 
http://links.lww.com/AA/C857) revealed reduced 
F1,6BP-to-F6P ratio in Intralipid-treated hearts (INS/
IL 0.47 ± 0.09 versus INS 0.59 ± 0.04; P  =  .035), but 
not in Omegaven-treated hearts (INS/OV 0.60 ± 
0.11 versus INS 0.59 ± 0.04; P =  .98), consistent with 
decreased activity of PFK-1 (Figure  3E). Tissue con-
centrations of citrate, an allosteric regulator of PFK-
1, were not different between groups (Figure  3F). 
Together, these data show reduced glucose uptake as 
a result of impaired glycolysis and glycogen synthesis 
in Intralipid-treated hearts, while Omegaven-treated 
hearts show unchanged glucose uptake because of 
preserved glycolytic flux.
Omegaven Inhibits PP2A and Enhances 
Phosphorylation of AktT308, p70S6KT389,  
and PFK-2S483
Based on our hypothesis that inhibition of PP2A activ-
ity would be involved in the observed beneficial effects 
of Omegaven on glycolytic flux, we determined PP2A 
phosphorylation and its methylation status, because 
both are known to affect PP2A activity.20,21 Omegaven 
increased phosphorylation at Y307, a phosphorylation 
site by receptor tyrosine kinases and Src kinase family 
members,20 compared to Intralipid treatment or insu-
lin treatment alone (Figure  4A). The demethylation 
status of PP2A was unaffected (Supplemental Digital 
Figure 2.  Glucose uptake, glycolysis, and glycogen metabolism. A, Glucose uptake was calculated from glycolytic flux and glycogen synthesis 
over 60 min in all groups. B, Average rates of glycolysis without insulin (first 30 min, open bars) and with insulin (subsequent 60 min, hatched 
bars). Horizontal brackets indicate significant differences for factor “time.” C, Total and radiolabeled (hatched bars) glycogen tissue content 
at the end of perfusions. N = 7 for each group. *Significantly different from no-INS group. †Significantly different from both the INS and INS/
OV groups. Data are mean (SE). ANOVA indicates analysis of variance; gdw, gram dry heart weight; INS, insulin alone; INS/IL, perfusion with 
insulin plus Intralipid; INS/OV, perfusion with insulin plus Omegaven; KW, Kruskal-Wallis; no-INS, perfusion without insulin; SE, standard error.
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Content, Figure 1A, http://links.lww.com/AA/C857). 
Increased phosphorylation of PP2A was accompanied 
by increased AktT308 and p70S6KT389 phosphorylation 
(Figure  4B, C). No changes in AktS473 were observed 
(Figure  4D). PFK2, the downstream target of PDK1/
Akt signaling, did not show changes in phosphoryla-
tion at S466 with Intralipid or Omegaven (Figure 4E), 
but there was an increased phosphorylation at S483 
with Omegaven, indicating enhanced PFK2 activity 
(Figure 4E). Phosphorylation of AMPK was not affected 
by Intralipid or Omegaven (Supplemental Digital 
Content, Figure 1B, http://links.lww.com/AA/C857).
Omegaven but Not Intralipid Causes 
Accumulation of Acylcarnitines and NFκB 
Activation
To determine the effect of the lipid emulsions 
Intralipid and Omegaven on cellular fatty acid 
uptake and β-oxidation, we established the acylcar-
nitine profiles (Supplemental Digital Content, Table 
4, http://links.lww.com/AA/C857). Omegaven-
treated hearts showed elevated free carnitine levels 
without decrease in acetylcarnitine, consistent with 
reduced cellular fatty acid uptake compared with the 
other groups (Figure 5A). CD36 in the membrane frac-
tion was not different between groups (Supplemental 
Digital Content, Figure 1C, http://links.lww.com/
AA/C857). There was accumulation of most other 
acylcarnitine species. Short-, medium-, and to a 
lesser degree, long-chain acylcarnitines (mainly 
C16:1, C18:1, and long-chain hydroxyl [OH]) were 
increased in Omegaven- but not Intralipid-treated 
hearts (Figure  5B–E), consistent with decelerated 
β-oxidation (Supplemental Digital Content, Table 3, 
http://links.lww.com/AA/C857). The acylcarnitine 
profile also showed a reduction in the low-abundance 
Figure 3.  Key regulators of cardiac glucose metabolism. A, PDH activity. B, PDK4 expression normalized to vinculin. C, GLUT4 in membrane 
fractions normalized to Na+/K+-ATPase. D, Phosphorylation of GSK3β normalized to total GSK3β. E, Phosphofructokinase-1 activity as mea-
sured by the ratio between glycolytic metabolites F-1,6bisP and F-6P. F, Citrate tissue concentrations. N = 7 for each group. †Significantly dif-
ferent from both the INS and INS/OV groups. Data are mean (SD). ANOVA indicates analysis of variance; F-1,6bisP, fructose 1,6-bisphosphate; 
F-6P, fructose 6-phosphate; GLUT4, glucose transporter type 4; GSK3β, glycogen synthase kinase 3β; INS, insulin alone; INS/IL, perfusion 
with insulin plus Intralipid; INS/OV, perfusion with insulin plus Omegaven; KW, Kruskal-Wallis; Na+/K+-ATPase, sodium-potassium adenosine 
triphosphatase; PDH, pyruvate dehydrogenase; PDK4, pyruvate dehydrogenase kinase 4; SD, standard deviation.
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C18:2 species exclusively in Intralipid-treated hearts, 
consistent with an increase in β-oxidation, because 
this low-abundance acylcarnitine species is specifi-
cally sensitive to flux changes in β-oxidation because 
it is poorly cleaved from triglycerides by lipopro-
tein lipase.22 To evaluate whether the decelerated 
β-oxidation and accumulation of acylcarnitines in 
Omegaven-treated hearts were associated with a 
higher reactive oxygen species (ROS) release from 
mitochondria,19,23 we measured the activation of the 
ROS-sensitive biomarker NFκB.24 Indeed, Omegaven 
was associated with higher NFκB activation when 
compared with insulin-treatment alone (INS/OV 
5.0 ± 0.9 absorbance/mg versus INS 3.5 ± 1.3 absor-
bance/mg; P  =  .038) (Figure  5F). This observation 
suggests that a decelerated β-oxidation accompanied 
by accumulation of acylcarnitines causing a prooxi-
dant environment may be involved in inhibiting the 
redox-sensitive PP2A and preserving the phosphory-
lation status of key insulin signaling proteins.
DISCUSSION
A recent study showed that acute exposure of cardio-
myocytes to marine n3 fatty acids prevented insulin 
resistance.13 But it is not clear so far whether acute 
exposure of n3 as opposed to n6 fatty acids has ben-
eficial effects on glucose metabolism in the intact 
beating heart, and if so, what the underlying mecha-
nisms could be. We have addressed these questions 
by using isolated perfused rat hearts under standard-
ized conditions of work load, insulin challenge, and 
energy substrate concentrations, comparing the effects 
of Omegaven versus Intralipid on glucose metabo-
lism. Our study shows the following salient findings. 
The use of the n3 fatty acid–based lipid emulsion 
Omegaven as opposed to Intralipid fully preserved 
Figure 4.  Serine/threonine PP2A and phosphorylation status of key insulin signaling proteins. A, Phosphorylation (Y307) of PP2A normal-
ized to total PP2A. Increased phosphorylation at Y307 indicates inhibition. B, Phosphorylation (T308) of Akt normalized to total Akt. C, 
Phosphorylation of p70S6K (T389) to total p70S6K. D, Phosphorylation (S473) of Akt normalized to total Akt. E, Phosphorylation of PFK2 
(S466, S483) normalized to total PFK2. Immunoblots of phospho- and total PFK2 were first separately normalized to vinculin (see Methods). 
N = 7 for each group. *Significantly different from INS group. #Significantly different from INS/IL group. Data are mean (SD). ANOVA indicates 
analysis of variance; INS, insulin alone; INS/IL, perfusion with insulin plus Intralipid; INS/OV, perfusion with insulin plus Omegaven; KW, 
Kruskal-Wallis; p70S6K, p70S6 kinase; PFK2, phosphofructokinase-2; PP2A, protein phosphatase 2A; SD, standard deviation.
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the metabolic response to insulin and maintained 
glycolysis, glycogen synthesis, and glucose uptake. 
Omegaven-mediated preserved glucose uptake was 
associated with preserved PFK1 activity, the rate-lim-
iting enzyme of glycolysis. The presence of Omegaven 
enhanced phosphorylation of the key insulin signaling 
proteins AktT308, but not AktS473, p70S6KT389, and PFK-2 
(PFK2S483), consistent with PP2A inhibition (Figure 6). 
Activated PFK2 produces more fructose 2,6-bispho-
sphate (F2,6BP), the key allosteric activator of PFK1, 
which offsets effects by the Randle cycle, that is, inhi-
bition of glycolysis by fatty acids.9 Our experiments 
have further explored possible mechanisms underly-
ing Omegaven-mediated PP2A inhibition and pin-
point to a potential role of a decelerated β-oxidation 
with accumulation of acylcarnitine species fostering 
a prooxidant cellular environment that potentially 
inhibits redox-sensitive PP2A21 enhancing insulin 
signaling.14,20
Glycolysis is regulated by insulin through activa-
tion of PFK2, the enzyme-synthetizing F2,6BP, which is 
a potent activator of PFK1, the rate-limiting enzyme of 
glycolysis. Although PFK2 was previously recognized 
as an Akt substrate and found to be phosphorylated and 
activated by Akt at S466 and S483, more recent research 
pinpoints PDK1 rather than Akt as the upstream kinase, 
where S466 phosphorylation is thought to increase 
the maximum rate of reaction (Vmax) and S483 phos-
phorylation is thought to reduce citrate inhibition.25 
Consistent with this concept is the observation that 
insulin fails to stimulate PFK2 in PDK1-deficient mice 
in vivo.26 Our own results from Omegaven-treated rat 
hearts show a selective phosphorylation of AktThr308 
and phosphorylation of PFK2 at S483 (but not S466) 
in accordance with observations in insulin-treated rat 
cardiomyocytes.27 We also found phosphorylation and 
activation of p70S6K,28 which reportedly reduces PFK2 
protein degradation via autophagy.29 Our studies in 
intact beating hearts demonstrate that modulation of 
PFK2 phosphorylation by Omegaven is involved in the 
preservation of glycolytic flux and glycogen synthesis 
(most likely allosterically by glucose itself30) despite the 
presence of palmitate in the perfusate and additional 
exposure to fatty acids released from Omegaven.
Figure 5.  Acylcarnitine tissue profiles. A, Free carnitine tissue levels (C0). B, Short-chain (C3–C6) acylcarnitine tissue levels. C, Medium-chain 
(C8–C12) acylcarnitine tissue levels. D, Long-chain (C14−C18) acylcarnitine tissue levels. E, OH-ACs tissue levels. F, NFkB DNA-binding activity 
in cardiac tissues measured from nuclear extracts. N = 7 for each group. *Significantly different from INS group. #Significantly different from 
INS/IL group. Data are mean (SD). ANOVA indicates analysis of variance; DNA, deoxyribonucleic acid; INS, insulin alone; INS/IL, perfusion 
with insulin plus Intralipid; INS/OV, perfusion with insulin plus Omegaven; NFkB, nuclear factor-kB; OH-AC, long-chain hydroxyl acylcarnitine; 
SD, standard deviation.
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PP2A accounts for 80% of total serine/threonine 
phosphatase activity and represents a major propor-
tion of protein phosphatases in mammalian cells.21 
PP2A specifically dephosphorylates AktT308,
31 PFK2,32 
and p70S6K,28 and possibly PDK1.33 PP2A is inhib-
ited by phosphorylation at Y307 by receptor tyrosine 
kinases including the insulin receptor,20 but also has 
the capability to reactivate itself by auto-dephosphor-
ylation.21 In our study, inhibition of PP2A could be 
mediated by activation of Src,20 which phosphorylates 
and inhibits PP2A at Y307. In fact, EPA and DHA, n3 
fatty acids released from Omegaven, have been shown 
to activate Src in a redox-sensitive manner, which sub-
sequently enhances Akt signaling in cultured coro-
nary endothelial cells.34 Alternatively, PP2A could be 
directly inhibited by ROS,23 which could impair auto-
dephosphorylation and its reactivation. There was no 
inhibition of PP2A as evidenced by phosphorylation 
at Y307 in the Intralipid group and the small changes 
in phosphorylation at Akt (T308) and p70S6K (T389) 
in this group may be due to the overall changed met-
abolic conditions in the presence of additional fatty 
acids. Together, our findings highlight the potential 
role of PP2A inhibition in n3 fatty acid–induced mod-
ulation and preservation of insulin signaling and glu-
cose metabolism in the intact beating heart.
We reasoned that the different fatty acids released 
by lipoprotein lipase from the 2 lipid emulsions 
Intralipid and Omegaven would elicit a characteris-
tic acylcarnitine profile, which could help understand 
the effects of Omegaven on glucose metabolism. The 
acylcarnitine profiles showed 2 major findings: (1) 
Omegaven decreased the uptake of fatty acids into 
cardiomyocytes, as evidenced by higher free carni-
tine levels, in the presence of unchanged acetylcarni-
tine and without reducing CD36 in the sarcolemma. 
This is in line with previous studies showing that 
long-chain n3 fatty acids, specifically EPA and DHA, 
inhibit the hydrolysis of triglyceride emulsions. The 
presence of >20% n3 fatty acids inhibited hydrolysis 
by 50%, and Omegaven contains >40% of EPA and 
DHA. Levy and Herzog22 have meticulously assessed 
the hydrolysis of individual fatty acids of chylomi-
cron triacylglycerol by cardiac lipoprotein lipase and 
Figure 6.  Working model of n3 fatty acid–induced preservation of insulin signaling and glucose uptake in the intact heart. Release of 
n3-PUFAs including EPA (C20:5 n3) and DHA (C22:6 n3) by LPL from Omegaven and their subsequent degradation in peroxisomes and 
mitochondria leads to accumulation of acylcarnitine species causing formation of ROS and inhibition of the redox-sensitive serine/threonine 
PP2A. Preservation of the phosphorylation status of its targets Akt (at Thr308), PFK2, which in turn activates PFK1 via its product fructose 
2,6-bisphosphate, and p70S6K, which leads to reduced ubiquitination of PFK2, maintains glycolytic flux in response to insulin stimulation. 
PDK1 is possibly an additional target of PP2A. NFκB signaling is also affected by PP2A and ROS. CD36 indicates cluster of differentiation 
36; DHA, docosahexaenoic; EPA, eicosapentaenoic; F1,6BP, fructose 1,6-bisphosphate; F2,6BP, fructose 2,6-bisphosphate; F6P, fructose 
6-phosphate; G6P, glucose 6-phosphate; GLUT4, glucose transporter type 4; IκBα, nuclear factor of κ light polypeptide gene enhancer in B 
cell inhibitor α; IKκβ, inhibitor of nuclear factor κB kinase subunit β; IR, insulin receptor; IRS1, insulin receptor substrate 1; LPL, lipoprotein 
lipase; n3 acyl-CoAs, n3 fatty acyl-CoA thioesters; n3-PUFA, n3 polyunsaturated fatty acids; NFκB, nuclear factor κB; p70S6K, p70S6 kinase; 
PDH, pyruvate dehydrogenase; PDK1, 3-phosphoinositide-dependent protein kinase-1; PFK1, phosphofructokinase-1; PFK2, phosphofructo-
kinase-2; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; 
PP2A, protein phosphatase 2A; pS, phosphorylated serine residue; pT, phosphorylated threonine residue; pY, phosphorylated tyrosine residue; 
ROS, reactive oxygen species; TCA, tricarboxylic acid cycle.
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found that the average mobilization of a long-chain 
fatty acid within 60 minutes is ≈25% as opposed to 
EPA with only 6% and DHA with only 2% mobiliza-
tion, respectively. In addition, as EPA and DHA are 
also transported via CD36, the main transporter of 
fatty acids into cardiomyocytes, the sterically curved 
polyunsaturated fatty acids as opposed to straight 
linear saturated fatty acids such as palmitate could 
impair the CD36 transport mechanism and reduce 
the overall uptake.35 It is therefore possible that a 
decrease in fatty acid uptake may have contributed 
to the reduced inhibition of glycolysis through lower 
citrate tissue concentrations, that is, the Randle cycle, 
but we did not observe decreased citrate tissue levels 
in Omegaven-treated hearts. However, small changes 
in compartmentalized citrate concentrations may 
be difficult to detect. (2) Omegaven-treated hearts 
showed accumulation of acylcarnitines, consistent 
with decelerated β-oxidation. While peroxisomes are 
the major site of degradation of very long chain and 
unsaturated fatty acids, most degradation steps of 
fatty acids also occur in mitochondria.36 The degrada-
tion of n3 polyunsaturated fatty acids imposes a sub-
stantial metabolic burden on β-oxidation. As double 
bonds in naturally occurring fatty acids are cis, but the 
β-oxidation can only handle trans double bonds at the 
enoyl-CoA hydratase step, 2 additional enzymes are 
required, namely a cis-trans isomerase, and an  epim-
erase.36 These additional steps slow down β-oxidation 
and may lead to significant accumulation of acyl-
carnitine species, as observed in Omegaven-treated 
hearts. Although increased β-oxidation intermedi-
ates can cause mitochondrial stress and are often 
considered a hallmark of the diabetic metabolism,23 
some studies report an improvement of glucose oxi-
dation with n3 fatty acid–induced acylcarnitines 
accumulation.12 Because previous studies reported 
ROS formation and activation of NFκB in response 
to acylcarnitine species,37 we tested the activation of 
NFκB as ROS biosensor and found that Omegaven- 
as opposed to Intralipid-treated hearts showed NFκB 
activation. Rutkowsky et al37 showed ROS production 
by C14 acylcarnitines from nonmitochondrial sources 
with concomitant NFκB activation in RAW264.7 
cells. We have also shown ROS formation directly 
from mitochondria in response to palmitoylcarni-
tine, possibly via inhibition of the electron transport 
chain.19 Interestingly, ROS-mediated PP2A inhibition 
is also known to activate NFκB in an nuclear factor 
of κ light polypeptide gene enhancer in B-cell inhibi-
tor α (IκBα)-dependent38 and independent manner.39 
Irrespectively, the cellular prooxidant environment 
and the accumulation of β-oxidation intermediates 
activated NFκB as observed in our own experiments.
Potential Clinical Implications
Lipid emulsions are clinically used for parenteral nutri-
tion in critically ill patients. They form an important 
part of all parenteral nutrition formulations because 
they provide essential fatty acids and the necessary 
density of calories. However, they also elicit insulin 
resistance,10,11 which is known to cause adverse clini-
cal outcomes.5 Although we did not observe reduced 
cardiac function in our study of healthy perfused rat 
hearts under aerobic conditions, it is likely that insu-
lin resistance may cause further harm to the already 
stressed critically ill patient and reduce cardiac func-
tion and tolerance against ischemia–reperfusion 
injury.40,41
Limitations of the Study
We did not directly measure F2,6BP in cardiac tissue, 
but our experiments imply that the increase in PFK1 
activity is due to higher amounts of its key allosteric 
activator F2,6BP, generated by the phosphorylated and 
activated PFK2. Unfortunately, F2,6BP is only present 
in very low tissue concentrations and subject to great 
instability and thus cannot be measured by standard 
metabolic approaches. Additional experiments will 
be necessary to ultimately prove that ROS formation 
is indeed the actual cause of the preserved insulin 
signaling in hearts treated with n3 fatty acids. These 
experiments should also determine the source of ROS 
production (NADPH oxidases versus electron trans-
port chain). Although inhibition and not activation of 
NFκB have been shown in other noncardiac tissues, 
mainly inflammatory cells, in response to n3 fatty acids, 
our observation in the heart that acute exposure to n3 
fatty acids elicits NFκB signaling is still compatible with 
beneficial effects because NFκB signaling is also known 
to play a role in cardioprotection.42 It will be important 
to determine whether Omegaven is also able to pre-
serve glucose metabolism in diseased lipid-overloaded 
diabetic hearts. Finally, although the exact compositions 
of the soybean oil–derived Intralipid and the fish oil–
derived Omegaven may slightly vary, the compositions 
of these 2 commercially available lipid emulsions are 
usually very consistent and stable. Nonetheless, there 
may be additional less well-characterized compounds 
in the 2 emulsions, which could theoretically account 
for some of the observed differences in insulin signaling 
and metabolism. However, a myriad of previous stud-
ies identified the difference in the released fatty acid 
species (specifically the ratio between n6 and n3 fatty 
acids) as the major cause of differences in metabolic out-
comes when comparing these 2 lipid emulsions.
In summary, our study addressed an important 
knowledge gap whether differences in the composi-
tion of lipid emulsions lead to differing degrees of 
insulin sensitivity in the heart. Using isolated per-
fused hearts, we show that Omegaven as opposed 
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to Intralipid preserves glucose uptake via the PP2A–
Akt–PFK pathway. The presence of n3 fatty acids 
appears to decelerate β-oxidation causing acylcarni-
tine species accumulation and a prooxidant response, 
potentially inhibiting redox-sensitive PP2A and pre-
serving the phosphorylation state of key insulin sig-
naling proteins and ultimately glucose uptake. E
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